Keybanc Maintains Overweight on DuPont de Nemours, Lowers Price Target to $82
Keybanc analyst Aleksey Yefremov maintains DuPont de Nemours (NYSE:DD) with a Overweight and lowers the price target from $96 to $82.
These Analysts Update Price Targets On Netflix Following Q2 Results
Netflix, Inc (NASDAQ: NFLX) posted better-than-expected earnings for its second quarter. The company ended the second quarter with 220.67 million subscribers, down from a reported 221.64 million in the first quarter.
Keybanc Maintains Overweight on Entegris, Lowers Price Target to $132
Keybanc analyst Aleksey Yefremov maintains Entegris (NASDAQ:ENTG) with a Overweight and lowers the price target from $150 to $132.
Keybanc Maintains Overweight on Eastman Chemical, Lowers Price Target to $124
Keybanc analyst Aleksey Yefremov maintains Eastman Chemical (NYSE:EMN) with a Overweight and lowers the price target from $142 to $124.
Piper Sandler Maintains Overweight on Essex Property Trust, Lowers Price Target to $320
Piper Sandler analyst Alexander Goldfarb maintains Essex Property Trust (NYSE:ESS) with a Overweight and lowers the price target from $340 to $320.
Piper Sandler Maintains Overweight on Centerspace, Lowers Price Target to $95
Piper Sandler analyst Alexander Goldfarb maintains Centerspace (NYSE:CSR) with a Overweight and lowers the price target from $100 to $95.
Piper Sandler Maintains Overweight on Camden Prop Trust, Lowers Price Target to $155
Piper Sandler analyst Alexander Goldfarb maintains Camden Prop Trust (NYSE:CPT) with a Overweight and lowers the price target from $160 to $155.
SVB Leerink Initiates Coverage On Kymera Therapeutics with Market Perform Rating, Announces Price Target of $26
SVB Leerink analyst Mike Kratky initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Market Perform rating and announces Price Target of $26.
SVB Leerink Initiates Coverage On Morphic Holding with Outperform Rating, Announces Price Target of $45
SVB Leerink analyst Mike Kratky initiates coverage on Morphic Holding (NASDAQ:MORF) with a Outperform rating and announces Price Target of $45.
Citigroup Maintains Buy on Johnson & Johnson, Lowers Price Target to $201
Citigroup analyst Joanne Wuensch maintains Johnson & Johnson (NYSE:JNJ) with a Buy and lowers the price target from $205 to $201.